V8 Peptides — Engineered Performance
Research Library
KPV in Animal Studies: Published Parameters and Math
KPVPreclinical

KPV in Animal Studies: Published Parameters and Math

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What parameters do published KPV animal studies report? Published abstracts describe mouse colitis models (DSS, TNBS, CD45RBhi transfer) with KPV given in drinking water or loaded into nanoparticle-hydrogel systems. Amounts are not recommended here. Preparation reduces to formulas: C = m ÷ V, aliquot mass = C × v, and molarity = C ÷ MW (about 342.4 g/mol). For laboratory research use only.

People searching for KPV animal-model protocols usually want two things: how the peptide was prepared, and what the published studies actually did. Both can be answered from the literature without recommending anything, and without any human-use framing. This article collects what the abstracts of key preclinical studies report about the vehicle, route and model, explains the concentration arithmetic as a formula, and lists the questions a lab should settle before it designs a protocol of its own. For laboratory research use only; not for human consumption.

Product facts come from the KPV research vials page, which lists 5 mg and 10 mg lyophilized vials, ≥98% HPLC purity and storage at 2–8 °C with −20 °C for long-term storage. Background on the molecule is in the KPV research overview and what is KPV.

What counts as a protocol in published KPV work

A published KPV animal study is not a recipe but a bundle of choices: species, disease-induction method, vehicle, route, schedule, read-outs. The abstracts below report some of these choices and leave others to the full text, which should always be read before anything is reproduced. The figure that follows is therefore a map of what was reported, not a template.

Study (model)Vehicle or route as reported in the abstractRead-outs reported
Dalmasso et al. [1]: DSS and TNBS colitis, miceKPV added to the drinking water (oral)Histology and pro-inflammatory cytokine mRNA expression
Kannengiesser et al. [2]: DSS colitis, CD45RBhi transfer colitis, MC1R-deficient miceNot specified in the abstract; check the full textBody-weight recovery, histology, myeloperoxidase activity, survival
Laroui et al. [3]: DSS colitis, miceKPV loaded into nanoparticles inside a polysaccharide hydrogelInflammatory and histologic parameters
Xiao et al. [4]: ulcerative-colitis mouse modelOral; HA-functionalized nanoparticles in a chitosan/alginate hydrogelMucosal damage and TNF-α
Watanabe et al. [5]: IL-1β-induced ear edema, miceIntraperitoneal and intracerebroventricular; α-MSH analogs, not KPV aloneEar edema

Vehicle and route: what the abstracts say

Two reported strategies stand out. In the original PepT1 work, KPV was supplied in the drinking water of mice with chemically induced colitis, and the authors linked its effect to uptake through the di/tripeptide transporter PepT1, which is expressed in intestinal epithelial and immune cells [1]. Later studies targeted the colon by packaging KPV into polymeric nanoparticles inside a polysaccharide hydrogel; one report states that this allowed similar efficacy at a concentration 12,000-fold lower than KPV in free solution [3], and another used hyaluronic-acid-functionalized particles in a chitosan/alginate hydrogel [4]. The delivery systems are covered in a companion article on nanoparticle and hydrogel delivery research.

The only parenteral routes in the table, intraperitoneal and intracerebroventricular, belong to a paper on α-MSH analogs with a D-valine substitution; it reported that the full-length α-MSH and its D-valine analog were equipotent by either route, while a shorter α-MSH(8-13) analog was less potent [5]. That study does not show what KPV itself does by those routes, so it should not be cited as KPV evidence.

The model comes first: how colitis is induced

The vehicle matters less than the model, because colitis models differ in what drives inflammation. A protocol paper on chemically induced mouse colitis describes updated methods for acute and chronic disease induced by TNBS, oxazolone and dextran sodium sulfate (DSS), which are different agents with different induction protocols [6]. A separate review of murine models stresses that the interpretation of colitis depends on mucosal immunology, on genetic and immunologic defects in the mice and on the intestinal microbiome [7]. Because the KPV studies above used DSS, TNBS or CD45RBhi transfer models, any replication has to match the induction method, the mouse strain and the microbial status of the colony as well as the peptide.

The detail of each model is the subject of the article on murine colitis studies; here the point is only that peptide preparation cannot be separated from the model it goes into.

Solution preparation as a formula

Per-product volume tables are intentionally not given here; the arithmetic is the same for any vial and is done for a specific lot with the reconstitution calculator. The relationships are:

QuantityFormulaNotes
Stock concentrationC = m ÷ Vm is the peptide mass stated for the vial, V the diluent volume added
Mass in an aliquotma = C × vv is the aliquot volume
DilutionC1V1 = C2V2Use to reach a working concentration from the stock
Molar concentrationM = C ÷ MWKPV, C16H30N4O4, has a molecular weight of about 342.4 g/mol
Unit check1 nM of a 342.4 g/mol peptide = 0.342 µg/LCell studies are reported in nM or µM; animal studies often in mg/mL or mg/kg

The last row is a reminder that in vitro and in vivo studies report in different units, so comparing them means converting through the molecular weight. A nanomolar effect in cultured cells does not translate into a delivered amount in an animal, because delivery, absorption and degradation intervene.

Vehicle compatibility and loss at surfaces

For an aqueous vehicle the main practical issues are dissolution, sterility and loss to surfaces. KPV is a very short, polar peptide, and short peptides dissolve quickly; the general reasoning in how to reconstitute a lyophilized peptide applies. Peptides do adsorb to some plasticware and glassware, and recovery depends on the tube material [8], so choosing tube type deliberately and keeping transfers few helps keep the working concentration close to the calculated one.

Whether the preparation needs a preservative-containing diluent or a sterile one depends on whether the stock will be entered several times; the trade-offs are discussed in bacteriostatic water explained. For drinking-water-type delivery the reported studies give no stability data in the abstracts, so the real concentration at the end of an exposure interval is an open question that a replication would have to measure.

Questions to settle before any protocol is written

  1. What identity and purity are documented? Read the batch documentation on the COA page and compare it with the identity cited in the paper being reproduced; see KPV purity testing.
  2. What counterion is present? Peptide salts of different counterions can behave differently in assays; the chemistry article on KPV synthesis covers why.
  3. What is the endpoint? Histology, myeloperoxidase activity and cytokine mRNA are not interchangeable, and each has noise of its own.
  4. What is the control set? Vehicle-only, an uninduced group and, where the claim is about a mechanism, a comparator peptide.
  5. What ethical and regulatory approvals apply? Any animal work needs institutional approval before it begins; this article does not substitute for it.

These questions apply regardless of the compound. They are listed because the abstracts above rarely state the details that decide reproducibility, and the full papers should be consulted.

What the animal literature does not show

The reported colitis studies support a narrow statement: in mouse models of chemically induced or transfer-induced colitis, KPV in the forms tested was reported to reduce inflammatory readouts. They do not establish a mechanism that holds across species, nor a transferable amount, nor effects in any condition not modeled. The comparison with the parent hormone, in which the full-length peptide and melanocortin receptors are involved, is covered in KPV vs α-MSH. Another limit is publication detail: abstracts seldom state strain, sex, age, housing or randomization, all of which shift colitis severity and therefore the apparent size of any peptide effect. For the broader literature map, see the article on reading the KPV literature.

Frequently asked questions

Which animal models have been used with KPV?

Published abstracts describe DSS colitis, TNBS colitis and CD45RBhi transfer colitis in mice, including mice with a non-functional melanocortin-1 receptor.

How was KPV delivered in the published mouse studies?

One study added it to drinking water. Others loaded it into nanoparticles inside a hydrogel. Routes in some studies are not stated in the abstract and must be read in the full text.

Does this article give amounts to use?

No. It reports what published studies described and gives concentration arithmetic as formulas only. Use the reconstitution calculator for the figures of a specific lot.

What is the formula for stock concentration?

Concentration equals peptide mass divided by diluent volume. Mass per aliquot equals concentration times aliquot volume.

How do I convert nM to µg/mL for KPV?

Multiply the molar concentration by the molecular weight of about 342.4 g/mol. One nanomolar corresponds to roughly 0.342 ng/mL.

Is a cell-culture concentration relevant to an animal study?

Not directly. Delivery, absorption and degradation separate the amount given from the concentration reaching target cells.

Does the nanoparticle result mean KPV needs lower concentrations?

One report states similar efficacy at a concentration 12,000-fold lower than free KPV when delivered in nanoparticles within a hydrogel. That is a single-model finding.

Why is the colitis model important?

DSS, TNBS and transfer models use different induction methods, so a result in one cannot be assumed in another.

Can KPV be stored in solution for a study?

No validated duration is published in the cited work. Set a written limit, freeze single-use portions, and re-verify concentration when it matters.

Where does α-MSH analog work fit?

It compared full-length α-MSH with a D-valine analog and a shorter analog by two routes, but it did not test KPV itself, so it should not be cited as KPV evidence.

Related reading: KPV Antimicrobial Properties In Vitro: An Assay Guide, KPV in Inflammation Research Models: Pathways, Readouts, KPV in Murine Colitis Models: DSS, TNBS and Transfer.

References

  1. Dalmasso G, Charrier–Hisamuddin L, Thu Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026
  2. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. doi:10.1002/ibd.20334
  3. Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D. Drug-Loaded Nanoparticles Targeted to the Colon With Polysaccharide Hydrogel Reduce Colitis in a Mouse Model. Gastroenterology. 2010;138(3):843-853.e2. doi:10.1053/j.gastro.2009.11.003
  4. Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. 2017;25(7):1628-1640. doi:10.1016/j.ymthe.2016.11.020
  5. Watanabe T, Hiltz ME, Catania A, Lipton JM. Inhibition of IL-1β-induced peripheral inflammation by peripheral and central administration of analogs of the neuropeptide α-MSH. Brain Research Bulletin. 1993;32(3):311-314. doi:10.1016/0361-9230(93)90192-e
  6. Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12(7):1295-1309. doi:10.1038/nprot.2017.044
  7. Kiesler P, Fuss IJ, Strober W. Experimental Models of Inflammatory Bowel Diseases. Cellular and Molecular Gastroenterology and Hepatology. 2015;1(2):154-170. doi:10.1016/j.jcmgh.2015.01.006
  8. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR. The importance of using the optimal plasticware and glassware in studies involving peptides. Analytical Biochemistry. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.